Are GDNF receptors the gatekeepers of GDNF efficacy during progressive nigrostriatal neuron loss?
Objective: To determine if GDNF receptor expression levels in the striatum or substantia nigra (SN) change in relation to differences in tyrosine hydroxylase (TH) and…Genetic outcomes of South Asian Parkinsonism cohort: from a tertiary care hospital
Objective: To identify the genetic heterogeneity in 16 south Asian patient with Parkinson’s disease. Background: Parkinson’s disease(PD) is the second most progressive neurodegenerative disorder with…Clinical toolkits to improve conversations about Parkinson’s dementia
Objective: To co-produce, with people living with Parkinson’s and professionals, a pair of toolkits to improve conversations about Parkinson’s dementia in the clinic: one for…Experience of the LARGE-PD protocol in a health center in Buenos Aires, Argentina
Objective: Disseminate and inform the activity of the Latin American Research Consortium on the Genetics of Parkinson's Disease (LARGE-PD) in Argentina. Background: The LARGE-PD consortium…The epigenetic association of Parkinson’s disease risk gene- GPNMB rs199347 with drinking
Objective: This paper examines the epigenetic association of rs199347 polymorphism variants of the GPNMB with drinking and DNA methylation changes. Background: Neuroinflammatory response induced by alcohol…Does hyposmia induce apathy in early Parkinson’s disease? Lessons from structural brain connectivity
Objective: To study changes in microstructural integrity of white matter tracts associated with apathy in patients with early Parkinson’s disease (PD) and hyposmia Background: Smells…LRRK2 kinase activity regulates sphingolipid hydrolase enzymatic activities in different cell lines: induced pluripotent stem cell-derived dopaminergic neurons, primary monocyte‐derived macrophages and SH-SY5Y
Objective: To assess whether inhibition of the kinase activity of LRRK2 affects changes in enzyme activity of sphingolipid hydrolase in the culture of dopaminergic neurons…Use of concomitant medications before and after treatment with levodopa/carbidopa intestinal gel in patients with advanced Parkinson’s disease: summary of phase 3 and real-world studies
Objective: Evaluate the use of concomitant Parkinson’s disease (PD) medications before and after treatment with levodopa/carbidopa intestinal gel (LCIG) using data from phase 3 clinical…Hypoxia‑induced astrocyte activation and its protective effect on Parkinson’s disease
Objective: In this study, we aimed to investigate whether hypoxic conditions can activate cerebral astrocytes and explore their protective effects on α-synuclein pre-formed fibril (PFF)-treated…Improving inpatient medication management in hospitalized Parkinson’s patients
Objective: Develop a process for Parkinson's patients to provide individualized medication management to reduce length of stay,, mortality, 30-day readmissions, and increase patient satisfaction. Background:…
- « Previous Page
- 1
- …
- 243
- 244
- 245
- 246
- 247
- …
- 436
- Next Page »